Lymphoproliferative Disorder Treatment Market Size & Share, by Route of Administration (Oral, Parenteral); Drug Class (Immunomodulatory Agents, Steroids, Cytotoxic Agents); Application (Leukemia, Lymphomas); Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2777
  • Published Date: Mar 17, 2023
  • Report Format: PDF, PPT

Companies Dominating the Lymphoproliferative Disorder Treatment Landscape

    • Atara Biotherapeutics, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck & Co., Inc.
    • Bristol Myers Squibb Company
    • Genentech, Inc.
    • ADC Therapeutics SA
    • AbbVie Inc.
    • Novartis AG
    • Pfizer Inc.
    • AstraZeneca
    • Gilead Sciences, Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • ADC Therapeutics SA disclosed its Phase 2 clinical trial findings for camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma. Cami has been examined in a key Phase 2 clinical trial in individuals who have relapsed or refractory Hodgkin lymphoma, as well as a Phase 1b clinical trial in tumor cells as monotherapy and in combination with pembrolizumab.

  • Genentech, Inc. has announced that the FDA has granted approval for Lunsumio (mosunetuzumab-axgb) for the treatment of adult individuals who have relapsed or refractory (R/R) follicular lymphoma (FL) following two or more lines of systemic therapy. This indication has been granted rapid approval based on the response rate.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2777
  • Published Date: Mar 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide expanding prevalence of lymphoma cases, rise in the cases of chronic lymphocytic leukemia (CLL), and an upsurge in novel targeted treatments are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

Poor access to healthcare facilities in developing countries, and lack of awareness in emerging nations regarding the lymphoproliferative disorders are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Atara Biotherapeutics, Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Genentech, Inc., ADC Therapeutics SA, AbbVie Inc., Novartis AG, Pfizer Inc., and others.

he company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by route of administration, drug class, application, distribution channel, and by region.

The immunomodulatory agents segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying